Sugi Predict

Sugi Predict / Compounds / SCHEMBL418664

SCHEMBL418664

SCHEMBL418664

O=C(O)[C@](O)(c1ccccc1)C1CCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 1.00
▸ NFE2L2 Q16236 1/20 1.00
▸ CHRM3 P20309 12/20 0.59
▸ CHRM2 P08172 6/20 0.59
▸ CHRM1 P11229 5/20 0.59
▸ ALDH1A1 P00352 2/20 0.55
▸ CHRM4 P08173 1/20 0.52
▸ CHRM5 P08912 1/20 0.52
▸ HRH1 P35367 1/20 0.52
▸ HTR2B P41595 1/20 0.52
▸ KCNH2 Q12809 1/20 0.52
▸ CYP1A2 P05177 1/20 0.52
▸ POLB P06746 1/20 0.52
▸ CYP3A4 P08684 1/20 0.51
▸ CYP2D6 P10635 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2062949 1.00 KEAP1 (1.00) KEAP1NFE2L2CHRM3CHRM2CHRM1
SCHEMBL415801 1.00 KEAP1 (1.00) KEAP1NFE2L2CHRM3CHRM2CHRM1
Iodide SCHEMBL16713396 0.98 KEAP1 (0.96) KEAP1NFE2L2CHRM3CHRM2CHRM1
SCHEMBL2764243 0.98 KEAP1 (0.96) KEAP1NFE2L2CHRM3CHRM2CHRM1
SCHEMBL198312 0.98 KEAP1 (0.96) KEAP1NFE2L2CHRM3CHRM2CHRM1
SCHEMBL1235433 0.98 KEAP1 (0.96) KEAP1NFE2L2CHRM3CHRM2CHRM1
SCHEMBL198082 0.98 KEAP1 (0.96) KEAP1NFE2L2CHRM3CHRM2CHRM1
SCHEMBL3909615 0.98 KEAP1 (0.96) KEAP1NFE2L2CHRM3CHRM2CHRM1
Hydrochloric Acid SCHEMBL7269393 0.98 KEAP1 (0.96) KEAP1NFE2L2CHRM3CHRM2CHRM1
SCHEMBL29903954 0.98 KEAP1 (0.96) KEAP1NFE2L2CHRM3CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034095-A1 GLYCOPYRROLATE SALTS JOURNEY MEDICAL CORP (US) 2026-02-05 — — US claimed
US-20250186395-A1 GLYCOPYRROLATE SALTS JOURNEY MEDICAL CORP (US) 2025-06-12 — — US claimed
EP-3842419-B1 METHOD OF MAKING THREO GLYCOPYRROLATE TOSYLATE JOURNEY MEDICAL CORP (US) 2024-04-03 — — EP claimed
CN-115925603-A Preparation method of Sopyraum bromide 山东齐都药业有限公司 2023-04-07 — — CN claimed
US-20220233500-A1 GLYCOPYRROLATE SALTS SWK FUNDING LLC 2022-07-28 — — US claimed
US-11291652-B2 Glycopyrrolate salts JOURNEY MEDICAL CORPORATION (US) 2022-04-05 — — US claimed
EP-2569308-B1 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES ALMIRALL SA (ES) 2016-11-23 — — EP claimed
CN-102190619-B Novel synthesis method for levorgyration demethyl phencynonate INST PHARM & TOXICOLOGY AMMS 2013-07-31 — — CN claimed
EP-2121615-B1 NAPADISYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR ALMIRALL SA (ES) 2012-03-28 — — EP claimed
CN-1824663-B Preparation method of pentethyl quinamidine optical isomer INST PHARM & TOXICOLOGY AMMS 2011-02-09 — — CN claimed
EP-2225241-A2 DERIVATIVES OF N-PHENYL-IMIDAZOÝ1,2-A¨PYRIDINE-2-CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF Sanofi-Aventis (FR) 2010-09-08 — — EP claimed
US-20100222393-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2010-09-02 — — US claimed
US-20100004215-A1 COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2010-01-07 — — US claimed
EP-2111861-A1 Compositions of phosphodiesterase type IV inhibitors Ranbaxy Laboratories Limited (IN) 2009-10-28 — — EP claimed
WO-2009106748-A2 DERIVATIVES OF N-PHENYL-IMIDAZO[1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2009-09-03 — — WO claimed
EP-1968945-A2 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-09-17 — — EP claimed
WO-2007077510-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2007-07-12 — — WO claimed
CN-1824663-A Preparation method of pentethyl quinamidine optical isomer INST OF TOXIC AND MEDICINE ACA (CN) 2006-08-30 — — CN claimed
US-20260034095-A1 GLYCOPYRROLATE SALTS JOURNEY MEDICAL CORP (US) 2026-02-05 — — US disclosed
EP-0823423-A1 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 1998-02-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222393-A1 MUSCARINIC RECEPTOR ANTAGONISTS CHRM3, CHRM2, CHRM1 KEAP1 1792/4885NFE2L2 1877/4885CHRM3 1/4885
US-11291652-B2 Glycopyrrolate salts GYPA, GHSR, GALR3 KEAP1 4551/4885NFE2L2 4835/4885CHRM3 317/4885
US-20250186395-A1 GLYCOPYRROLATE SALTS GYPA, GHSR, GALR3 KEAP1 4551/4885NFE2L2 4835/4885CHRM3 317/4885
US-20260034095-A1 GLYCOPYRROLATE SALTS SLC6A13, THRB, SLC13A3 KEAP1 4879/4885NFE2L2 4633/4885CHRM3 24/4885
US-20100004215-A1 COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS PDE4B, PDE4A, PDE3B KEAP1 3733/4885NFE2L2 4066/4885CHRM3 88/4885
US-20220233500-A1 GLYCOPYRROLATE SALTS GYPA, GHSR, GALR3 KEAP1 4551/4885NFE2L2 4835/4885CHRM3 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.